Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
3-11 mEq/dL; (positives - negatives)
|
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
0.1-0.2 ng/dL; <3 and skeletal muscle
|
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
>130 desirable; 130-159 borderline high risk; >160 high risk
|
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
.8-2.7 ng/dL; most accurate
|
|
|
Term
| Total Tyiiodothyronine T3 |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| International Normalized Ratio |
|
Definition
|
|
Term
| activated Partial Prothrombin Time (aPPT) |
|
Definition
|
|
Term
|
Definition
|
4.6-6.5 E6 cells/mm3 M; 4.6-5.4 E6 F
|
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Prostate Specific Antigen (PSA) |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Antinuclear Antibodies (ANA) |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Erythrocyte Sedimentation Rate, ESR |
|
Definition
|
1-15 mm/hr M; 1-20 mm/hr F
|
|
|